Beone Medicines Ltd.

ONC · Nasdaq · ·

对比

US$416.41+0.1%11月13日收盘

数据截至2026年9月30日，来自2026年11月5日提交的10-Q

1W: +2.3%
1M: +11.3%
3M: +19.8%

Beone Medicines Ltd.（ONC）股票——这是一门好生意吗？ — InspectStocks

Beone Medicines Ltd.

ONC · Nasdaq · ·

对比

US$416.41+0.1%11月13日收盘

数据截至2026年9月30日，来自2026年11月5日提交的10-Q

1W: +2.3%
1M: +11.3%
3M: +19.8%

Just reported

Q3 2026 results

From Beone Medicines's results release of 2026年11月5日; its quarterly report has since been filed.

Revenue
Actual
US$1.89B
+34% y/y
+11% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$3.25
+213% y/y
+56% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$418.7M
+157% y/y
+29% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$6.9B – US$7B+30% y/y First given
Operating income, adjustedUS$1.9B – US$2BFirst given
Operating income, GAAPUS$1.2B – US$1.3B+180% y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

怎么赚钱

Sales of cancer medicines98%

各项收入占比是对Q1 2026的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.

再显示 3 项

XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.

谁在买2

Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.

靠什么支撑，什么会击垮它

业务依赖什么

1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.

可能出什么问题

1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.

完整财务报表 →

关于Beone Medicines Ltd.

BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.

总部: Basel, Switzerland
成立于: 2010
员工人数: More than 12,000 (Q2 2026, medium)
上市于: Nasdaq
财年结束: December 31

基于 Beone Medicines Ltd. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

Just reported